Bryostatin-1 and IL-2 synergize to induce IFN-γ expression in human peripheral blood T cells: Implications for cancer immunotherapy

Journal of Immunology

Volumn 167, Issue 9, 2001, Pages 4828-4837

  Curiel, R E ^a   Garcia, C S ^a   Farooq, L ^a   Aguero, M F ^a   Espinoza Delgado, I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SYNAPTOPHYSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NORTHERN BLOTTING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035501099     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.9.4828     Document Type: Article

References (68)

1. Isolation and structure of bryostatin-1
2. Bryostatin 1: Will the oceans provide a cancer cure?
3. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells
4. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor
5. Bryostatins: Potent, new mitogens that mimic phorbol ester tumor promoters
6. Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells
7. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
8. Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity in vitro
9. Bryostatin 1: A potential anti-leukemic agent for chronic myelomonocytic leukemia
10. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines
11. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2
12. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines
13. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells
14. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
15. Successful treatment of murine melanoma with bryostatin 1
16. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity
17. The antineoplastic agent bryostatin-1 induces proin-flammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2Rγ chain expression
18. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation
19. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: Comparison with effects of bryostatin 1 on lymphocyte function in vitro
20. Activation of human T lymphocytes by bryostatin
21. Bryostatin 1-activated T cells can traffic and mediate tumor regression
22. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1
23. Phase 1 study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo: The Cancer Research Campaign Phase 1 Committee
24. The IFNγ receptor: A paradigm for cytokine receptor signaling
25. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
26. IL-12 induces T helper I-directed antitumor response
27. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
28. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas
29. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
30. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
31. Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor γ chain gene expression in human monocytes
32. Site-specific mutagenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues
33. Enhanced B7-2 gene expression by interferon-γ in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms
34. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids
35. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
36. The nuclear factor YY1 suppresses the human γ interferon promoter through two mechanisms: Inhibition of AP1 binding and activation of a silencer element
37. Negative transcriptional regulation of the interferon-γ promoter by glucocorticoids and dominant negative mutants of c-Jun
38. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
39. + T cell adhesion to B cells
40. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway
41. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: Dependance on CD28 signaling and preferential inhibition of IL-10 production
42. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
43. The p38 mitogen-activated protein kinase is required for IL-12 induced IFN-γ expression
44. The expanding universe of T-cell subsets: Th1, Th2 and more
45. Roles of IL-4 and IFN-γ in stabilizing the T helper cell type 1 and 2 phenotype
46. Impaired development of Th2 cells in IL-13-deficient mice
47. IL-4/IL-3 signaling beyond JAK/STAT
48. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
49. Co-induction of lymphokine synthesis by the antineoplastic bryostatins
50. + T lymphocytes
51. Regulation of interferon-γ mRNA in a cytolytic T cell clone: Ca(2+)-induced transcription followed by mRNA stabilization through activation of protein kinase C or increase in cAMP
52. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12): Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2
53. AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation
54. Localization and physical mapping of genes encoding the A+U-rich element RNA-binding protein AUF1 to human chromosomes 4 and X
55. Structure of the human immune interferon gene
56. Alterations in NFκB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy
57. Cellular and molecular mechanisms of IFN-γ production induced by IL-2 and IL-12 in a human NK cell line
58. 4 pituitary cells
59. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostafin 1
60. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth
61. +, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-γ: Role of phosphatidyl serine
62. A novel transcription factor, T-bet, directs Th1 lineage commitment
63. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells
64. The role of IL-13 and its receptor in allergy and inflammatory responses
65. The related cytokines interleukin-13 and interleukin-14 are distinguished by differential production and differential effects on T lymphocytes
66. Regulation pf T helper type 2 cell immunity by inter-leukin-4 and interleukin-13
67. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells
68. Bryostatin-1 and low dose IL-2 is as efficient as high dose IL-2 without the acute toxicity